Kerry Anne Rambaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kerry Anne Rambaran has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Abigail Elmes-Patel
Department of Pharmacy Practice University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication - Alexa Maisenbach
Prime Saint Joseph Joliet Joliet Illinois USA
1 shared publication - Alexander F. Infante
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication - Alyssa Robertson
Department of Pharmacy WellSpan Health York Hospital York Pennsylvania USA
1 shared publication Amy Lehnert
Department of Pharmacy Practice, KGI School of Pharmacy, Claremont, CA, United States
1 shared publication- Angela Kerins
American College of Clinical Pharmacy Lenexa Kansas USA
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (6) , e70227
Role of the Emergency Medicine Pharmacist in the Management of Boarding Patients: An Opinion of the Emergency Medicine Practice and Research Network of the American College of Clinical Pharmacy Endorsed by the SAEM Academy of Emergency Medicine Pharmacists and the Society of Emergency Medicine Pharmacists
As emergency department (ED) crowding and patient boarding reach critical levels nationwide, the role of the emergency medicine pharmacist (EMP) must be both defined and safeguarded. While EMPs are increasingly valued for their contributions to acute care, their responsibilities often unintentionally expand during periods of operational strain, particularly when admitted patients remain in the ED for prolonged durations. EMPs should ideally be resourced to remain focused on time‐sensitive, high‐risk medication management where their expertise is most impactful and not be used as default providers for all pharmacotherapy needs during ED boarding. This perspective outlines our position on the ideal scope of EMP practice during times of congestion, advocating for clearly defined role boundaries, strategic collaboration with other pharmacy team members, and system‐level support to prevent dilution of emergency care. EMPs must be empowered to prioritize critical ED workflows, support resuscitations, and lead initiatives in education, protocol development, and patient safety, without being overextended by responsibilities that can be absorbed by other team members.
- 20 May 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (6) , e70227
Open AccessRole of the Emergency Medicine Pharmacist in the Management of Boarding Patients: An Opinion of the Emergency Medicine Practice and Research Network of the American College of Clinical Pharmacy Endorsed by the SAEM Academy of Emergency Medicine Pharmacists and the Society of Emergency Medicine Pharmacists
As emergency department (ED) crowding and patient boarding reach critical levels nationwide, the role of the emergency medicine pharmacist (EMP) must be both defined and safeguarded. While EMPs are increasingly valued for their contributions to acute care, their responsibilities often unintentionally expand during periods of operational strain, particularly when admitted patients remain in the ED for prolonged durations. EMPs should ideally be resourced to remain focused on time‐sensitive, high‐risk medication management where their expertise is most impactful and not be used as default providers for all pharmacotherapy needs during ED boarding. This perspective outlines our position on the ideal scope of EMP practice during times of congestion, advocating for clearly defined role boundaries, strategic collaboration with other pharmacy team members, and system‐level support to prevent dilution of emergency care. EMPs must be empowered to prioritize critical ED workflows, support resuscitations, and lead initiatives in education, protocol development, and patient safety, without being overextended by responsibilities that can be absorbed by other team members.
- 3 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 500-510
Pharmacists' contributions to the management of opioid use disorder
Clinicians continue to work toward ending the opioid‐related overdose and death epidemic in the United States. Opioid use disorder (OUD) is a chronic and relapsing disease characterized by an overpowering desire to use opioids despite serious adverse effects, impairment, or distress. Management of OUD requires team‐based care. Pharmacists are uniquely positioned to contribute to the management of OUD in all stages and have demonstrated positive outcomes. Pharmacists are the most accessible health care professionals in community settings, and they practice in all settings across the health care continuum. However, opportunities exist to bridge the disparity between the demand for treatment and its availability. Regulatory barriers limit innovation and expansion of pharmacy services. This white paper describes pharmacists' contributions to the management of OUD and identifies opportunities to leverage pharmacists within the health care landscape to improve patient outcomes.
- 3 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 500-510
Pharmacists' contributions to the management of opioid use disorder
Clinicians continue to work toward ending the opioid‐related overdose and death epidemic in the United States. Opioid use disorder (OUD) is a chronic and relapsing disease characterized by an overpowering desire to use opioids despite serious adverse effects, impairment, or distress. Management of OUD requires team‐based care. Pharmacists are uniquely positioned to contribute to the management of OUD in all stages and have demonstrated positive outcomes. Pharmacists are the most accessible health care professionals in community settings, and they practice in all settings across the health care continuum. However, opportunities exist to bridge the disparity between the demand for treatment and its availability. Regulatory barriers limit innovation and expansion of pharmacy services. This white paper describes pharmacists' contributions to the management of OUD and identifies opportunities to leverage pharmacists within the health care landscape to improve patient outcomes.
- Open Access
- 7 November 2022
- Published by Elsevier in American Journal of Medicine Open
- Vol. 8
Corticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease
- 7 November 2022
- Published by Elsevier in American Journal of Medicine Open
- Vol. 8
Open AccessCorticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease
- 1 January 2019
- Published by Elsevier
- p. 183-195
Positive inotropic drugs and drugs used in dysrhythmias
- 1 January 2019
- Published by Elsevier
- p. 183-195
Positive inotropic drugs and drugs used in dysrhythmias
- 24 July 2018
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (4) , 884-890
Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation
Background: Infection is the most common cause of morbidity and mortality in patients undergoing myleosuppressive therapy with the risk of infection being heightened during the neutropenic phase. Fluoroquinolones are most often utilized as prophylaxis, specifically levofloxacin or ciprofloxacin; however, there is increasing resistance among these agents. The objective of this study is to compare the efficacy of ciprofloxacin and levofloxacin when used prophylactically in hematopoietic stem cell transplantation patients. Study design: A retrospective cohort study conducted at a 443-bed tertiary teaching county hospital from 1 January 2005 to 31 September 2016. Methods: Patients aged 18–89 who were admitted and received levofloxacin or ciprofloxacin post hematopoietic stem cell transplantation were evaluated. Results: The patient population (N = 151) was predominantly male (93 vs. 58) and the median (IQR) age was 57 (20.1) years. There were 108 patients undergoing autologous hematopoietic stem cell transplantation compared to 43 undergoing allogenic hematopoietic stem cell transplantation. Significantly fewer patients who received levofloxacin (11/43, 25.6%) developed neutropenic fever compared to patients who received ciprofloxacin (61/108, 56.5%, p = 0.0006). Also there were significantly more positive blood cultures in the ciprofloxacin group (36/108, 33.3%) compared to the levofloxacin group (4/43, 9.3%); the majority of which were Gram-positive organisms (p = 0.0025). Conclusion: Prophylaxis with levofloxacin was associated with a lower incidence of febrile neutropenia and bacteremia when compared to ciprofloxacin in hematopoietic stem cell transplantation patients.
- 24 July 2018
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (4) , 884-890
Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation
Background: Infection is the most common cause of morbidity and mortality in patients undergoing myleosuppressive therapy with the risk of infection being heightened during the neutropenic phase. Fluoroquinolones are most often utilized as prophylaxis, specifically levofloxacin or ciprofloxacin; however, there is increasing resistance among these agents. The objective of this study is to compare the efficacy of ciprofloxacin and levofloxacin when used prophylactically in hematopoietic stem cell transplantation patients. Study design: A retrospective cohort study conducted at a 443-bed tertiary teaching county hospital from 1 January 2005 to 31 September 2016. Methods: Patients aged 18–89 who were admitted and received levofloxacin or ciprofloxacin post hematopoietic stem cell transplantation were evaluated. Results: The patient population (N = 151) was predominantly male (93 vs. 58) and the median (IQR) age was 57 (20.1) years. There were 108 patients undergoing autologous hematopoietic stem cell transplantation compared to 43 undergoing allogenic hematopoietic stem cell transplantation. Significantly fewer patients who received levofloxacin (11/43, 25.6%) developed neutropenic fever compared to patients who received ciprofloxacin (61/108, 56.5%, p = 0.0006). Also there were significantly more positive blood cultures in the ciprofloxacin group (36/108, 33.3%) compared to the levofloxacin group (4/43, 9.3%); the majority of which were Gram-positive organisms (p = 0.0025). Conclusion: Prophylaxis with levofloxacin was associated with a lower incidence of febrile neutropenia and bacteremia when compared to ciprofloxacin in hematopoietic stem cell transplantation patients.
- 21 May 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (3) , 303-306
AH-7921: A review of previously published reports
AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, and there have been no clinical trials exploring the safety of AH-7921. Herein, we provide an analysis of existing case reports available in the literature regarding AH-7921. We searched PubMed, Scopus, Web of Science, and EBSCO for articles (up until December 2017) using the terms “AH-7921” and “AH7921.” In total, 48 articles were identified, and 5 articles were included in our review. A total of 14 cases were found, of which 13 resulted in fatalities. The oral route of administration was reported in two cases, and most cases reported use of concomitant pharmaceutical agents. Pulmonary edema was the most common finding postmortem among deceased cases, with nine of the cases having heavier lungs. Overall, fatalities occurred with low and high concentrations of AH-7921 in the femoral blood. We strongly encourage toxicology screenings for this novel opioid to be included when an overdose of an opioid of unknown nature is suggested.
- 21 May 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (3) , 303-306
AH-7921: A review of previously published reports
AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, and there have been no clinical trials exploring the safety of AH-7921. Herein, we provide an analysis of existing case reports available in the literature regarding AH-7921. We searched PubMed, Scopus, Web of Science, and EBSCO for articles (up until December 2017) using the terms “AH-7921” and “AH7921.” In total, 48 articles were identified, and 5 articles were included in our review. A total of 14 cases were found, of which 13 resulted in fatalities. The oral route of administration was reported in two cases, and most cases reported use of concomitant pharmaceutical agents. Pulmonary edema was the most common finding postmortem among deceased cases, with nine of the cases having heavier lungs. Overall, fatalities occurred with low and high concentrations of AH-7921 in the femoral blood. We strongly encourage toxicology screenings for this novel opioid to be included when an overdose of an opioid of unknown nature is suggested.
- 1 January 2018
- Published by Elsevier
- p. 229-241
Positive Inotropic Drugs and Drugs Used in Dysrhythmias
- 1 January 2018
- Published by Elsevier
- p. 229-241
Positive Inotropic Drugs and Drugs Used in Dysrhythmias